文献速递胸部肿瘤

晚期非小细胞肺癌化疗免疫/免疫治疗前预后因素分析

Pretherapeutic prognostic factors for survival under chemoimmunotherapy/immunotherapy of advanced NSCLC patients.
PubMed 文献 · Eur J Cancer · 2026-02-24

本研究回顾性分析120例接受单药或化疗联合免疫治疗的晚期非小细胞肺癌患者,将生存超过24个月的「超级应答者」与无进展生存不足10个月的原发进展者进行对比。单因素和多因素分析确认ECOG评分0分、LDH不高、CRP不高、PD-L1阳性及无KEAP1突变是总生存和无进展生存的独立预后因素,有助于识别早期治疗失败。

要点

  • ECOG 0分、LDH正常、CRP正常、PD-L1阳性、无KEAP1突变提示预后良好。
  • 上述五因素经多因素分析确认为OS和PFS的独立预后因素。
  • 研究聚焦于超级应答者与早期进展者的对比,有助于预测早期治疗失败。

核心结论

  • 在晚期非小细胞肺癌化疗免疫或单药免疫治疗中,初始ECOG 0分、LDH非升高、CRP非升高、治疗前PD-L1阳性及无KEAP1突变是OS和PFS的独立预后因素。
  • 这些因素有助于估计侵袭性肺癌进展患者的早期治疗失败。

研究设计与样本

  • 单中心回顾性分析,纳入120例符合条件的接受单药免疫或化疗免疫治疗的晚期非小细胞肺癌患者。
  • 将生存超过24个月的超级应答者与无进展生存小于10个月的原发进展者进行对比,采用单因素和多因素统计方法分析。

主要发现

  • 单因素分析发现ECOG状态、PD-L1 TPS、血清LDH、血清CRP和KEAP1突变五个因素对总生存有影响。
  • 多因素分析确认上述因素的独立影响,并在无进展生存中通过单因素和多因素分析得到 comparable 支持。

关键数值与推荐

  • 总生存的独立预后因素包括:初始ECOG为0、LDH非升高、CRP非升高、治疗前PD-L1阳性、无KEAP1突变。
  • 无进展生存分析支持上述相同因素的独立影响。

临床怎么用

  • 治疗前可综合评估ECOG评分、LDH、CRP、PD-L1表达及KEAP1突变状态,辅助判断患者接受免疫治疗的预后。
  • 对具有不良预后因素的患者,需警惕早期治疗失败和侵袭性进展,加强监测。

局限性

  • 回顾性研究,样本量120例,患者经过选择(超级应答者与原发进展者对比)。
  • 结论需在更大规模、更少选择的人群中前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Checkpoint inhibitor therapy with PD-1/PD-L1-antibodies has significant benefits in non-small-cell lung cancer treatment even in advanced stage IVA/B. While PD-L1 expression in tumor is a weak but relevant predictor of treatment response, impact and interaction of potential prognostic factors like ECOG status, LDH-levels, CRP-levels, and genetic mutations remain so far undefined. This study aims to identify pretherapeutic factors that could help estimate outcome of NSCLC patients undergoing chemoimmunotherapy or mono-immunotherapy. PATIENTS AND METHODS: In our Comprehensive Cancer Centre we retrospectively analyzed two selective patient groups undergoing treatment with mono- or chemoimmunotherapy. 'Super responders' with long-term survival longer than 24 months were contrasted against primary progressors with progression-free survival of less than 10 months. Factors were analyzed with univariate and multivariate statistical methods. RESULTS: In 120 patients fulfilling the inclusion criteria we found signals for five factors with impact on overall survival in univariate analyses: ECOG-status, PD-L1 TPS, serum LDH, serum CRP and KEAP-1 mutation. Multivariate analyses confirmed independent impact. As a confirmatory analysis the impact of these factors on progression-free survival was investigated. Comparable impact was supported by univariate and multivariate analysis. CONCLUSION: A detailed prognostic factor analysis for overall survival and progression-free survival in selected groups of advanced non-small-cell lung cancer patients under chemo- or mono-immunotherapy identified five independent parameters: initial ECOG of zero, non-elevated LDH, non-elevated CRP, pretreatment PD-L1 positivity and absence of KEAP1-mutation. Our findings are especially helpful of estimating early treatment failure with aggressive lung cancer progression. This important investigation will be prospectively confirmed in a larger, more unselected population at our Cancer Centre.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Judickiene J, Metzenmacher M, Zaun G, et al. Pretherapeutic prognostic factors for survival under chemoimmunotherapy/immunotherapy of advanced NSCLC patients. Eur J Cancer. 2026. PMID: 41780180. doi:10.1016/j.ejca.2026.116600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。